Skip to main content

Web Exclusives

FDA Approvals
Danyelza Receives FDA Approval for High-Risk Neuroblastoma in the Bone and Bone Marrow
Read More
FDA Approvals
Gavreto, a New RET Inhibitor, Now Approved for Thyroid Cancer with RET Fusions
Read More
Perspectives
The Dirty Dozen Redux
David B. Nash, MD, MBA
Read More
ESMO 2020 Highlights
Olaparib a New Option for Men with Metastatic Prostate Cancer and BRCA Mutation
Phoebe Starr
Read More
ESMO 2020 Highlights
Nivolumab New Standard of Care in Gastroesophageal Cancers as First-Line or Adjuvant Therapy
Phoebe Starr
Read More
Perspectives
UnHealthcare
David B. Nash, MD, MBA
Read More
Infectious Diseases
COVID-Related Death Rate Tripled in Patients with Cancer versus the General Population
Phoebe Starr
Read More
Disparities in Cancer Care, Oncology
AACR’s Cancer Disparities Inaugural Report Addresses Care Inequities
Wayne Kuznar
Read More
FDA Approvals
Opdivo Approved for Advanced Esophageal Squamous-Cell Carcinoma
Read More
FDA Approvals, Lung Cancer, Oncology
FDA Approves Cyramza plus Tarceva for First-Line Treatment of Metastatic NSCLC with EGFR Mutation
Read More
Page 15 of 37
Results 141 - 150 of 364